,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ABC7-42404400C24.1,,ENSG00000277758,,10,47750864-47763592,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA036971, HPA036972, HPA064559",Approved,,Approved,Golgi apparatus,,Not detected,Tissue enhanced,,cerebral cortex: 13.8;lung: 19.3,skin: 5.7,Cell line enriched,7.0,SK-BR-3: 45.1
1,ABCA3,"ABC-C, ABC3, EST111653, LBM180",ENSG00000167972,ATP binding cassette subfamily A member 3,16,2275881-2340746,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA007884,Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,lung: 135.5,cerebral cortex: 51.5,Cell line enhanced,,SCLC-21H: 53.9;T-47d: 71.7
2,ACP5,"HPAP, TRAP",ENSG00000102575,"Acid phosphatase 5, tartrate resistant",19,11574660-11579008,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB002584, HPA057655, HPA059463",Enhanced,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,lung: 254.0,lymph node: 86.3,Cell line enhanced,,BEWO: 36.2;SK-MEL-30: 85.3;U-138 MG: 97.5
3,ADAMTS8,"ADAM-TS8, FLJ41712, METH2",ENSG00000134917,ADAM metallopeptidase with thrombospondin type 1 motif 8,11,130404925-130428993,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at transcript level,HPA066349,Approved,,,,Endometrial cancer:1.38e-4 (favourable),Tissue enhanced,Tissue enhanced,,appendix: 10.9;lung: 15.5,seminal vesicle: 5.5,Cell line enhanced,,HMC-1: 3.2;NTERA-2: 1.8;U-2 OS: 8.7
4,ADGRF5,"DKFZp564O1923, GPR116, KIAA0758",ENSG00000069122,Adhesion G protein-coupled receptor F5,6,46852512-46954943,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:8.84e-5 (favourable),Expressed in all,Tissue enhanced,,lung: 157.8,adipose tissue: 76.2,Group enriched,8.0,HUVEC TERT2: 20.7;TIME: 61.2
5,AGBL1,"CCP4, FLJ32310",ENSG00000273540,ATP/GTP binding protein like 1,15,86079973-87029052,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,lung: 1.3;skeletal muscle: 4.4,esophagus: 1.0,Not detected,,
6,ALDH3B1,ALDH7,ENSG00000006534,Aldehyde dehydrogenase 3 family member B1,11,68008578-68029282,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA038525,Uncertain,,,,"Colorectal cancer:1.18e-4 (unfavourable), Pancreatic cancer:6.07e-4 (unfavourable)",Expressed in all,Tissue enhanced,,fallopian tube: 64.4;lung: 67.7,bone marrow: 30.7,Cell line enhanced,,A549: 137.9;CAPAN-2: 136.9
7,ALOX15,15-LOX-1,ENSG00000161905,Arachidonate 15-lipoxygenase,17,4630902-4642294,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004962, CAB004963, HPA013859",Approved,,,,,Mixed,Tissue enhanced,,fallopian tube: 19.6;lung: 9.8,breast: 4.7,Group enriched,7.0,HMC-1: 13.6;MCF7: 10.8;T-47d: 3.9
8,ALOX5,5-LOX,ENSG00000012779,Arachidonate 5-lipoxygenase,10,45374176-45446119,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA071285,Enhanced,,Supported,Nucleoplasm,"Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable)",Expressed in all,Tissue enhanced,,lung: 41.3,bone marrow: 28.8,Cell line enhanced,,BEWO: 10.4;Daudi: 22.8;HMC-1: 20.7;RT4: 14.0;U-266/70: 11.3
9,ALPL,"HOPS, TNSALP",ENSG00000162551,"Alkaline phosphatase, liver/bone/kidney",1,21509372-21578412,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007105, HPA008765, CAB020829",Enhanced,,Approved,Cytosol,Melanoma:7.08e-4 (unfavourable),Expressed in all,Tissue enhanced,,lung: 78.8,kidney: 47.2,Group enriched,8.0,HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8
10,C11orf16,,ENSG00000176029,Chromosome 11 open reading frame 16,11,8920076-8933006,Predicted intracellular proteins,Evidence at transcript level,,,,,,Endometrial cancer:3.32e-4 (favourable),Tissue enhanced,Tissue enhanced,,fallopian tube: 20.6;lung: 4.1,testis: 2.5,Not detected,,
11,C16orf89,MGC45438,ENSG00000153446,Chromosome 16 open reading frame 89,16,5044122-5066110,Predicted secreted proteins,Evidence at protein level,"HPA013613, HPA016934",Enhanced,,,,,Group enriched,Tissue enhanced,,lung: 145.4;thyroid gland: 352.5,epididymis: 94.3,Cell line enhanced,,ASC diff: 1.4;Hep G2: 1.7;NTERA-2: 1.5;U-2197: 2.0
12,C1orf116,"FLJ36507, MGC2742, MGC4309, SARG",ENSG00000182795,Chromosome 1 open reading frame 116,1,207018521-207032756,Predicted intracellular proteins,Evidence at protein level,"HPA011888, HPA011889",Enhanced,,Supported,Plasma membrane<br>Cytosol,Renal cancer:1.01e-5 (favourable),Mixed,Tissue enhanced,,esophagus: 112.4;lung: 109.2;prostate: 82.0,stomach: 54.9,Group enriched,5.0,A-431: 50.3;CAPAN-2: 87.3;HaCaT: 108.7;HBEC3-KT: 85.0;hTCEpi: 44.4;hTERT-HME1: 26.3;RPTEC TERT1: 42.8
13,C2,,ENSG00000166278,Complement C2,6,31897785-31945672,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB016775,Supported,,,,Renal cancer:2.64e-7 (unfavourable),Tissue enriched,Tissue enhanced,,liver: 86.3;lung: 42.6,placenta: 21.9,Group enriched,5.0,Hep G2: 30.0;Karpas-707: 94.7
14,C2orf91,,ENSG00000205086,Chromosome 2 open reading frame 91,2,41935368-41954266,Predicted intracellular proteins,Evidence at transcript level,HPA042517,Uncertain,,,,,Tissue enriched,Tissue enhanced,,lung: 2.5,adrenal gland: 1.0,Group enriched,6.0,AN3-CA: 3.8;HDLM-2: 13.8
15,C5orf38,"CEI, IRX2NB",ENSG00000186493,Chromosome 5 open reading frame 38,5,2752131-2755397,Predicted intracellular proteins,Evidence at protein level,HPA073667,,,Enhanced,Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,lung: 13.7;salivary gland: 13.0,skin: 8.5,Cell line enhanced,,BEWO: 79.2;hTCEpi: 32.4;SiHa: 37.3
16,CALCRL,"CGRPR, CRLR",ENSG00000064989,Calcitonin receptor like receptor,2,187343129-187448460,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA008070, HPA046515",Uncertain,,Supported,Plasma membrane,,Expressed in all,Tissue enhanced,,lung: 114.3,adipose tissue: 76.8,Cell line enhanced,,HUVEC TERT2: 145.5;RPTEC TERT1: 30.7;TIME: 20.7
17,CASS4,"C20orf32, HEFL, HEPL",ENSG00000087589,Cas scaffolding protein family member 4,20,56412112-56460387,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB034217,Approved,,,,,Mixed,Tissue enhanced,,appendix: 17.7;lung: 23.9,spleen: 10.7,Cell line enhanced,,HEL: 15.8;HMC-1: 45.4;K-562: 19.8
18,CAV1,CAV,ENSG00000105974,Caveolin 1,7,116524785-116561184,"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB003791, HPA049326",Enhanced,,Supported,Golgi apparatus,"Lung cancer:7.17e-5 (unfavourable), Renal cancer:1.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 859.9,adipose tissue: 640.4,Cell line enhanced,,LHCN-M2: 1943.1
19,CCDC190,"C1orf110, MGC48998",ENSG00000185860,Coiled-coil domain containing 190,1,162824458-162868815,Predicted intracellular proteins,Evidence at transcript level,"HPA028579, HPA028584, HPA028592",Uncertain,,Approved,Vesicles,,Mixed,Tissue enhanced,,esophagus: 3.7;lung: 2.8,fallopian tube: 0.8,Cell line enhanced,,hTEC/SVTERT24-B: 3.9;HUVEC TERT2: 4.0;LHCN-M2: 6.0;TIME: 13.6;U-2197: 8.2
20,CCL18,"AMAC-1, CKb7, DC-CK1, DCCK1, MIP-4, PARC, SCYA18",ENSG00000275385,C-C motif chemokine ligand 18,17,36064280-36072032,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enhanced,,adipose tissue: 20.9;lung: 13.0;tonsil: 10.5,lymph node: 6.2,Not detected,,
21,CD101,"IGSF2, V7",ENSG00000134256,CD101 molecule,1,117001750-117036476,"CD markers, Predicted membrane proteins",Evidence at protein level,"HPA049527, HPA057763",Approved,,Uncertain,Mitochondria,,Mixed,Tissue enhanced,,lung: 9.6,small intestine: 6.8,Cell line enriched,8.0,HMC-1: 24.0
22,CD300C,"CMRF-35A, CMRF35, CMRF35A, IGSF16, LIR",ENSG00000167850,CD300c molecule,17,74541108-74546143,"CD markers, Predicted membrane proteins",Evidence at transcript level,HPA014523,Approved,,,,Testis cancer:8.53e-5 (unfavourable),Mixed,Tissue enhanced,,lung: 12.4,appendix: 9.5,Cell line enhanced,,HEL: 6.4;HMC-1: 29.3;U-937: 12.8
23,CD300LF,"CD300f, CLM1, IGSF13, IREM1, NKIR",ENSG00000186074,CD300 molecule like family member f,17,74694311-74712978,"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA013712,Supported,,,,,Expressed in all,Tissue enhanced,,lung: 25.6;spleen: 28.0,appendix: 18.2,Group enriched,7.0,THP-1: 16.6;U-937: 37.2
24,CLEC14A,C14orf27,ENSG00000176435,C-type lectin domain family 14 member A,14,38254103-38256369,Predicted membrane proteins,Evidence at protein level,"HPA039468, HPA048119",Uncertain,,Supported,Endoplasmic reticulum<br>Golgi apparatus,Head and neck cancer:4.13e-6 (favourable),Expressed in all,Tissue enhanced,,lung: 76.1,adipose tissue: 40.9,Cell line enhanced,,fHDF/TERT166: 60.3;HUVEC TERT2: 345.4;TIME: 121.9
25,CLEC6A,"CLECSF10, dectin-2",ENSG00000205846,C-type lectin domain family 6 member A,12,8455926-8478330,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,appendix: 1.5;lung: 1.5,lymph node: 0.8,Cell line enhanced,,NTERA-2: 3.3
26,CLIC5,DFNB102,ENSG00000112782,Chloride intracellular channel 5,6,45898451-46080395,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA074371,,,Supported,Nuclear speckles<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,lung: 116.1;skeletal muscle: 119.2,heart muscle: 76.0,Group enriched,7.0,CAPAN-2: 13.3;EFO-21: 10.0;HDLM-2: 5.7;REH: 13.6;U-266/70: 10.5
27,CNTN6,NB-3,ENSG00000134115,Contactin 6,3,1092576-1404217,Predicted membrane proteins,Evidence at protein level,HPA016645,Uncertain,,,,,Group enriched,Tissue enhanced,,lung: 4.6;thyroid gland: 17.4,cerebral cortex: 4.0,Group enriched,22.0,AF22: 2.0;SH-SY5Y: 2.4
28,COL6A6,,ENSG00000206384,Collagen type VI alpha 6 chain,3,130560334-130678155,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA045239,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,lung: 11.2,breast: 2.9,Not detected,,
29,CRTAC1,"ASPIC1, CEP-68, FLJ10320",ENSG00000095713,Cartilage acidic protein 1,10,97865000-98030828,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008175,Enhanced,,,,"Endometrial cancer:5.01e-6 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Renal cancer:1.85e-4 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 51.0;fallopian tube: 63.6;lung: 76.3;seminal vesicle: 48.1,urinary bladder: 12.8,Cell line enhanced,,HUVEC TERT2: 6.0;SCLC-21H: 5.6;SK-MEL-30: 6.3;TIME: 8.0
30,CSF2,"GM-CSF, GMCSF",ENSG00000164400,Colony stimulating factor 2,5,132073790-132076170,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,"HPA057404, HPA062006",,,Enhanced,Vesicles,,Mixed,Tissue enhanced,,lung: 3.0,urinary bladder: 0.9,Cell line enhanced,,BJ hTERT+: 74.1;hTEC/SVTERT24-B: 20.9
31,CTD-3214H19.16,,ENSG00000269711,,19,7678501-7682854,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,bone marrow: 14.1;lung: 11.8,duodenum: 7.7,Cell line enhanced,,EFO-21: 12.1;HMC-1: 18.1;NB-4: 7.8;THP-1: 22.2;U-937: 19.1
32,CXCL17,"Dcip1, DMC, UNQ473, VCC1",ENSG00000189377,C-X-C motif chemokine ligand 17,19,42428288-42443048,Predicted secreted proteins,Evidence at protein level,,,,,,"Lung cancer:4.92e-5 (favourable), Pancreatic cancer:4.63e-4 (unfavourable)",Mixed,Tissue enhanced,,lung: 193.5;stomach: 289.7,esophagus: 83.1,Cell line enhanced,,RT4: 1.8
33,CYP4B1,,ENSG00000142973,Cytochrome P450 family 4 subfamily B member 1,1,46757838-46819413,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA004331,Approved,,Supported,Vesicles,Cervical cancer:5.99e-4 (favourable),Tissue enhanced,Tissue enhanced,,lung: 382.2,fallopian tube: 79.0,Cell line enriched,9.0,RT4: 234.9
34,DNAH5,"CILD3, Dnahc5, HL1, KTGNR, PCD",ENSG00000039139,Dynein axonemal heavy chain 5,5,13690331-13944543,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA037469, HPA037470",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,fallopian tube: 6.2;lung: 2.6,breast: 2.0,Cell line enhanced,,BJ hTERT+: 1.3;PC-3: 2.5;RPTEC TERT1: 1.1
35,EFCC1,"C3orf73, CCDC48, FLJ12057",ENSG00000114654,EF-hand and coiled-coil domain containing 1,3,129001629-129040742,Predicted intracellular proteins,Evidence at transcript level,"HPA042798, HPA050888",Uncertain,,,,Pancreatic cancer:9.70e-4 (favourable),Mixed,Tissue enhanced,,lung: 4.9,spleen: 3.6,Cell line enhanced,,AF22: 1.3;HL-60: 3.0
36,EMP2,XMP,ENSG00000213853,Epithelial membrane protein 2,16,10528422-10580698,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA014711,Approved,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:2.85e-8 (unfavourable), Glioma:1.93e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 343.9,skin: 166.6,Cell line enhanced,,MCF7: 205.4;SK-BR-3: 191.4
37,ESYT3,"CHR3SYT, FAM62C",ENSG00000158220,Extended synaptotagmin 3,3,138434586-138481686,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA039200,Approved,,,,Lung cancer:8.30e-4 (favourable),Tissue enhanced,Tissue enhanced,,lung: 8.4;skin: 7.5;thyroid gland: 8.5,endometrium: 3.7,Cell line enhanced,,NTERA-2: 4.1;SCLC-21H: 5.2;SiHa: 1.9
38,FBN3,,ENSG00000142449,Fibrillin 3,19,8065402-8149846,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049482,Uncertain,,,,Endometrial cancer:5.15e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,lung: 2.1;thyroid gland: 1.8,"cerebral cortex,salivary gland: 1.1",Cell line enhanced,,CACO-2: 3.1;NTERA-2: 12.3;REH: 16.9
39,FGFR4,"CD334, JTK2",ENSG00000160867,Fibroblast growth factor receptor 4,5,177086886-177098144,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB005196, HPA027273, HPA027369, HPA028251",Approved,,,,,Mixed,Tissue enhanced,,lung: 38.9,duodenum: 21.4,Cell line enhanced,,CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
40,FMO2,,ENSG00000094963,Flavin containing monooxygenase 2,1,171185208-171211230,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA028261,Approved,,,,,Mixed,Tissue enhanced,,adipose tissue: 98.3;esophagus: 102.9;lung: 158.2,breast: 55.8,Group enriched,48.0,ASC diff: 27.9;ASC TERT1: 12.9;HSkMC: 35.2
41,FOLR1,FOLR,ENSG00000110195,Folate receptor 1,11,72189558-72196323,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA077030,,,Approved,Nuclear membrane,Liver cancer:2.50e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 166.6;fallopian tube: 275.8;lung: 267.5",kidney: 152.7,Group enriched,6.0,HeLa: 298.2;RPTEC TERT1: 350.8
42,FOXA2,HNF3B,ENSG00000125798,Forkhead box A2,20,22581005-22585455,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB001388, HPA066846",Enhanced,,Supported,Nucleoplasm<br>Cell Junctions,"Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable)",Mixed,Tissue enhanced,,"cervix, uterine: 21.4;lung: 20.5;stomach: 31.0",liver: 11.5,Cell line enhanced,,A549: 16.1;HBEC3-KT: 14.5;Hep G2: 19.5;PC-3: 24.0;SCLC-21H: 52.3
43,GALNT5,GalNAc-T5,ENSG00000136542,Polypeptide N-acetylgalactosaminyltransferase 5,2,157257598-157314211,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA008963, HPA009035",Approved,,Approved,Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,lung: 18.4;rectum: 19.7;stomach: 16.8,colon: 13.9,Cell line enhanced,,A-431: 60.2;BJ hTERT+: 63.9;fHDF/TERT166: 72.0;HaCaT: 69.5;LHCN-M2: 65.2
44,GDF10,BMP-3b,ENSG00000266524,Growth differentiation factor 10,10,47300386-47313547,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA015498,Uncertain,,,,,Mixed,Tissue enhanced,,lung: 19.6,testis: 9.0,Cell line enhanced,,AF22: 14.6;MOLT-4: 2.6;SH-SY5Y: 6.4
45,GGT2,GGT,ENSG00000133475,Gamma-glutamyltransferase 2,22,21207973-21227637,Predicted membrane proteins,Evidence at protein level,"HPA045635, HPA047534, HPA065444",Supported,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,lung: 1.3;thyroid gland: 1.5,"breast,salivary gland: 0.9",Cell line enhanced,,HDLM-2: 1.5;HeLa: 2.0;U-2197: 8.2
46,GGTLC3,,ENSG00000274252,Gamma-glutamyltransferase light chain 3,22,18516344-18518161,Predicted intracellular proteins,Evidence at protein level,"HPA045635, HPA047534",Uncertain,,,,,Not detected,Tissue enhanced,,lung: 1.9;testis: 1.0,small intestine: 0.5,Cell line enhanced,,U-2197: 1.0
47,GPRC5A,"PEIG-1, RAI3, RAIG1, TIG1",ENSG00000013588,G protein-coupled receptor class C group 5 member A,12,12890782-12917937,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007928, HPA046526",Enhanced,,Enhanced,Vesicles<br>Plasma membrane,"Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable)",Mixed,Tissue enhanced,,lung: 302.0,thyroid gland: 91.3,Cell line enhanced,,CAPAN-2: 1167.5;SiHa: 520.3
48,GPRIN2,"KIAA0514, MGC15171",ENSG00000204175,G protein regulated inducer of neurite outgrowth 2,10,46549044-46555530,Predicted intracellular proteins,Evidence at protein level,HPA038129,Approved,,Approved,Nucleoplasm,"Endometrial cancer:8.60e-8 (unfavourable), Head and neck cancer:3.47e-4 (favourable)",Mixed,Tissue enhanced,,lung: 18.0;skin: 18.8,small intestine: 11.7,Group enriched,5.0,A-431: 12.9;A549: 38.1;SiHa: 8.3;SK-BR-3: 17.1
49,GRP,,ENSG00000134443,Gastrin releasing peptide,18,59220168-59230774,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,lung: 13.4;thyroid gland: 10.4,parathyroid gland: 3.9,Group enriched,8.0,BJ hTERT+: 4.2;fHDF/TERT166: 5.1
50,HAS3,,ENSG00000103044,Hyaluronan synthase 3,16,69105564-69118719,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA031554, CAB033850",Supported,,Approved,Microtubules,Pancreatic cancer:5.36e-4 (unfavourable),Group enriched,Tissue enhanced,,lung: 29.9;urinary bladder: 36.4,stomach: 11.8,Cell line enhanced,,HaCaT: 46.5;PC-3: 257.9;RT4: 89.2
51,HHIP,"FLJ20992, HIP",ENSG00000164161,Hedgehog interacting protein,4,144646021-144745271,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012616,Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,lung: 24.2,cerebral cortex: 10.8,Group enriched,6.0,HUVEC TERT2: 269.0;RH-30: 62.9;TIME: 306.5
52,HLA-C,"D6S204, HLA-JY3, PSORS1",ENSG00000204525,"Major histocompatibility complex, class I, C",6,31268749-31272130,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enhanced,,lung: 744.7,small intestine: 396.9,Cell line enhanced,,A-431: 660.6;EFO-21: 748.1;RPTEC TERT1: 346.0;U-266/70: 367.3;U-266/84: 281.2
53,HLA-DMA,"D6S222E, RING6",ENSG00000204257,"Major histocompatibility complex, class II, DM alpha",6,32948613-32969094,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012750, HPA017295",Enhanced,,Approved,Vesicles,"Endometrial cancer:4.64e-5 (favourable), Lung cancer:4.59e-4 (favourable)",Expressed in all,Tissue enhanced,,lung: 65.0,fallopian tube: 41.9,Cell line enhanced,,U-266/70: 22.0;U-266/84: 9.5;U-698: 52.4
54,HLA-DQA1,"CELIAC1, HLA-DQA",ENSG00000196735,"Major histocompatibility complex, class II, DQ alpha 1",6,32628179-32647062,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012315,Enhanced,,,,,Expressed in all,Tissue enhanced,,lung: 504.8,lymph node: 338.6,Cell line enriched,9.0,HDLM-2: 1315.9
55,HLA-DQB2,HLA-DXB,ENSG00000232629,"Major histocompatibility complex, class II, DQ beta 2",6,32756098-32763534,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Breast cancer:5.55e-4 (favourable),Expressed in all,Tissue enhanced,,lung: 8.1;skin: 13.3,tonsil: 5.9,Not detected,,
56,HLA-DRA,HLA-DRA1,ENSG00000204287,"Major histocompatibility complex, class II, DR alpha",6,32439842-32445046,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002798, CAB015402, HPA050162, HPA053176",Enhanced,,,,Colorectal cancer:5.30e-4 (favourable),Expressed in all,Tissue enhanced,,lung: 731.8;lymph node: 894.1,tonsil: 476.7,Cell line enhanced,,Daudi: 254.2;HDLM-2: 588.3;REH: 234.5;U-698: 247.8;U-87 MG: 236.0
57,HLA-DRB1,HLA-DR1B,ENSG00000196126,"Major histocompatibility complex, class II, DR beta 1",6,32578769-32589848,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB015400, CAB034021, HPA043151",Enhanced,,,,,Expressed in all,Tissue enhanced,,lung: 868.4,lymph node: 619.6,Cell line enhanced,,HDLM-2: 1095.2;U-87 MG: 302.0
58,HLA-DRB5,,ENSG00000198502,"Major histocompatibility complex, class II, DR beta 5",6,32517343-32530287,Predicted membrane proteins,Evidence at protein level,HPA043151,Supported,,,,Endometrial cancer:7.89e-4 (favourable),Expressed in all,Tissue enhanced,,lung: 530.8,lymph node: 397.6,Group enriched,7.0,HDLM-2: 589.3;HMC-1: 134.7;U-698: 129.3;U-87 MG: 232.1
59,HMCN1,"ARMD1, FBLN6, FIBL-6, FIBL6",ENSG00000143341,Hemicentin 1,1,185734551-186190949,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051677,Uncertain,,,,Renal cancer:3.59e-7 (unfavourable),Tissue enriched,Tissue enhanced,,lung: 22.3,prostate: 12.6,Group enriched,6.0,fHDF/TERT166: 17.3;MCF7: 58.7;SK-MEL-30: 38.8;U-138 MG: 13.5;WM-115: 43.4
60,HTR3C,,ENSG00000178084,5-hydroxytryptamine receptor 3C,3,184053047-184060671,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,lung: 1.9,duodenum: 0.4,Not detected,,
61,ICAM4,"CD242, LW",ENSG00000105371,Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group),19,10286967-10288522,"Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,bone marrow: 8.7;lung: 14.5,epididymis: 2.9,Cell line enhanced,,HEL: 67.4;K-562: 35.3;NB-4: 20.5
62,INMT,,ENSG00000241644,Indolethylamine N-methyltransferase,7,30697985-30757602,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA061343,,,Approved,Golgi apparatus<br>Vesicles,Liver cancer:5.72e-4 (favourable),Tissue enhanced,Tissue enhanced,,lung: 144.8,seminal vesicle: 66.2,Group enriched,6.0,CACO-2: 13.8;HHSteC: 5.7
63,IRX2,,ENSG00000170561,Iroquois homeobox 2,5,2745845-2751662,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA050895, HPA054669",Approved,,Approved,Nucleus<br>Nucleoli,Pancreatic cancer:8.84e-4 (favourable),Mixed,Tissue enhanced,,breast: 29.6;lung: 28.0,skin: 19.5,Cell line enhanced,,AF22: 100.0;BEWO: 58.5;hTCEpi: 47.9
64,IRX5,IRX-2a,ENSG00000176842,Iroquois homeobox 5,16,54930862-54934485,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047130,,,Approved,Nuclear speckles<br>Microtubules<br>Cytosol,Lung cancer:4.59e-4 (favourable),Tissue enhanced,Tissue enhanced,,breast: 17.9;lung: 9.6;skin: 10.1,salivary gland: 4.6,Cell line enhanced,,RPTEC TERT1: 20.1;T-47d: 34.4
65,ITGAE,"CD103, HUMINAE",ENSG00000083457,Integrin subunit alpha E,17,3714628-3801243,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB026461, HPA036313",Approved,,,,"Renal cancer:1.13e-8 (unfavourable), Endometrial cancer:1.04e-4 (favourable), Urothelial cancer:3.56e-4 (favourable), Pancreatic cancer:5.78e-4 (favourable)",Expressed in all,Tissue enhanced,,lung: 9.5,small intestine: 6.2,Cell line enriched,22.0,MOLT-4: 9.6
66,ITGB6,,ENSG00000115221,Integrin subunit beta 6,2,160099666-160271888,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA023626, CAB073536",Approved,,Approved,Nucleoplasm<br>Cell Junctions<br>Centrosome,Pancreatic cancer:5.03e-6 (unfavourable),Mixed,Tissue enhanced,,lung: 66.9,urinary bladder: 30.3,Cell line enhanced,,CAPAN-2: 122.2;RPTEC TERT1: 206.4
67,KCNK17,"K2p17.1, TALK-2, TALK2, TASK-4, TASK4",ENSG00000124780,Potassium two pore domain channel subfamily K member 17,6,39299001-39314553,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at transcript level,HPA043892,Uncertain,,,,,Mixed,Tissue enhanced,,lung: 5.6,placenta: 5.3,Cell line enriched,9.0,SCLC-21H: 91.6
68,KCNS3,Kv9.3,ENSG00000170745,Potassium voltage-gated channel modifier subfamily S member 3,2,17877847-18361616,"Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA014864,Approved,,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.53e-4 (unfavourable),Expressed in all,Tissue enhanced,,lung: 35.5,skeletal muscle: 29.6,Cell line enhanced,,RH-30: 66.9;RT4: 38.5
69,KHDC3L,"C6orf221, ECAT1",ENSG00000203908,"KH domain containing 3 like, subcortical maternal complex member",6,73362677-73364171,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA043699,Uncertain,,,,,Tissue enriched,Tissue enhanced,,lung: 1.0;testis: 2.2,epididymis: 0.4,Not detected,,
70,KHDRBS2,"MGC26664, SLM-1, SLM1",ENSG00000112232,"KH RNA binding domain containing, signal transduction associated 2",6,61679960-62286227,Predicted intracellular proteins,Evidence at protein level,"HPA000500, HPA029392",Supported,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.6;lung: 5.6;thyroid gland: 11.0,spleen: 1.8,Cell line enhanced,,AF22: 7.2;NTERA-2: 1.9;THP-1: 1.0
71,KIAA1324L,"EIG121L, FLJ31340",ENSG00000164659,KIAA1324 like,7,86876906-87059699,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA044527, HPA076093",Uncertain,,Approved,Endoplasmic reticulum,,Mixed,Tissue enhanced,,lung: 32.2,cerebral cortex: 21.7,Cell line enhanced,,K-562: 44.1;SCLC-21H: 45.6
72,KLRG2,"CLEC15B, FLJ44186",ENSG00000188883,Killer cell lectin like receptor G2,7,139452690-139483712,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018199,Uncertain,,,,Lung cancer:8.61e-4 (favourable),Tissue enriched,Tissue enhanced,,lung: 4.4;parathyroid gland: 5.7;thyroid gland: 6.8,kidney: 2.7,Cell line enhanced,,BEWO: 14.0;HAP1: 15.9;SCLC-21H: 8.6;SK-BR-3: 23.3
73,LPCAT1,"AGPAT10, AGPAT9, AYTL2, FLJ12443",ENSG00000153395,Lysophosphatidylcholine acyltransferase 1,5,1456480-1523977,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA012501, HPA022268",Enhanced,,Supported,Endoplasmic reticulum<br>Lipid droplets,"Liver cancer:1.88e-8 (unfavourable), Renal cancer:2.64e-7 (unfavourable), Pancreatic cancer:4.90e-5 (favourable), Cervical cancer:7.11e-5 (unfavourable), Endometrial cancer:3.67e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 19.0;spleen: 14.7,cerebral cortex: 4.4,Cell line enhanced,,BEWO: 80.0;EFO-21: 74.7;PC-3: 52.0
74,MARCO,SCARA2,ENSG00000019169,Macrophage receptor with collagenous structure,2,118942166-118994660,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA063793,Enhanced,,Approved,Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,appendix: 123.2;lung: 288.2,adipose tissue: 78.0,Cell line enhanced,,HaCaT: 1.5;THP-1: 1.7;U-2 OS: 2.7;U-266/70: 1.1
75,MATN3,"EDM5, HOA",ENSG00000132031,Matrilin 3,2,19992111-20012694,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA051250,,,Approved,Endoplasmic reticulum<br>Golgi apparatus,"Stomach cancer:4.74e-5 (unfavourable), Liver cancer:8.62e-5 (unfavourable), Cervical cancer:1.41e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 20.2;placenta: 16.5,seminal vesicle: 6.2,Cell line enriched,5.0,Hep G2: 98.9
76,MMP13,CLG3,ENSG00000137745,Matrix metallopeptidase 13,11,102942995-102955734,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,lung: 1.5;urinary bladder: 1.3,appendix: 0.3,Cell line enhanced,,HaCaT: 15.8;PC-3: 6.2
77,MRC1,"bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1",ENSG00000260314,Mannose receptor C-type 1,10,17809344-17911170,"CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA004114, HPA045134, CAB068203",Enhanced,,,,,Expressed in all,Tissue enhanced,,lung: 179.9,placenta: 77.6,Group enriched,22.0,MOLT-4: 15.4;TIME: 14.0
78,MS4A2,"APY, FCER1B, IGER, MS4A1",ENSG00000149534,Membrane spanning 4-domains A2,11,60088261-60098466,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA059967,Enhanced,,,,,Mixed,Tissue enhanced,,lung: 24.8,gallbladder: 18.4,Cell line enhanced,,HEL: 2.4;THP-1: 1.0
79,MSR1,"CD204, SCARA1",ENSG00000038945,Macrophage scavenger receptor 1,8,16107878-16567490,"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000272, CAB032491",Enhanced,,,,,Expressed in all,Tissue enhanced,,lung: 187.7,gallbladder: 50.2,Group enriched,6.0,BJ hTERT+: 86.3;REH: 37.8
80,MUC1,"ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM",ENSG00000185499,"Mucin 1, cell surface associated",1,155185824-155192916,"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB000036, CAB001986, HPA004179, HPA007235, HPA008855",Enhanced,,,,Pancreatic cancer:4.60e-4 (unfavourable),Expressed in all,Tissue enhanced,,lung: 448.0;stomach: 654.1,"cervix, uterine: 288.9",Group enriched,7.0,CAPAN-2: 1005.2;RPTEC TERT1: 654.7;T-47d: 360.0
81,NCKAP5,"ERIH1, ERIH2, NAP5",ENSG00000176771,NCK associated protein 5,2,132671799-133568463,Predicted intracellular proteins,Evidence at protein level,"HPA034639, HPA044859",Uncertain,,Approved,Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,lung: 17.3,"cerebral cortex,kidney: 4.4",Cell line enriched,7.0,AF22: 45.7
82,NDNF,"C4orf31, FLJ23191",ENSG00000173376,Neuron derived neurotrophic factor,4,121035613-121073021,Predicted secreted proteins,Evidence at protein level,HPA048881,,,Supported,Vesicles,Renal cancer:3.26e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,lung: 159.9;placenta: 86.6,ovary: 52.7,Cell line enhanced,,fHDF/TERT166: 37.8;U-266/70: 16.0;U-266/84: 60.4
83,NINJ2,,ENSG00000171840,Ninjurin 2,12,564296-663779,Predicted membrane proteins,Evidence at protein level,HPA058980,,,Approved,Endoplasmic reticulum,Head and neck cancer:5.31e-4 (favourable),Expressed in all,Tissue enhanced,,lung: 55.6,bone marrow: 23.9,Cell line enhanced,,HEL: 137.2;MOLT-4: 210.8
84,NKD2,Naked2,ENSG00000145506,Naked cuticle homolog 2,5,1008829-1038943,Predicted intracellular proteins,Evidence at protein level,HPA049463,Uncertain,,,,"Renal cancer:2.66e-5 (unfavourable), Melanoma:9.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 5.5;skin: 3.8,spleen: 2.9,Cell line enhanced,,BEWO: 17.2;NB-4: 11.0;RPMI-8226: 29.0
85,NOTCH4,INT3,ENSG00000204301,Notch 4,6,32194843-32224067,Predicted membrane proteins,Evidence at protein level,,,,,,Renal cancer:3.84e-4 (unfavourable),Expressed in all,Tissue enhanced,,lung: 12.1,thyroid gland: 4.2,Not detected,,
86,NPNT,"EGFL6L, POEM",ENSG00000168743,Nephronectin,4,105894775-106004027,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA003711, HPA050203",Supported,,Approved,Nucleus<br>Cell Junctions<br>Cytosol,Renal cancer:8.28e-8 (favourable),Expressed in all,Tissue enhanced,,lung: 168.4;thyroid gland: 276.0,prostate: 136.5,Cell line enhanced,,BEWO: 27.8;HeLa: 22.2;RPTEC TERT1: 28.6;T-47d: 48.1
87,OSCAR,,ENSG00000170909,"Osteoclast associated, immunoglobulin-like receptor",19,54094668-54102692,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:2.71e-5 (unfavourable),Expressed in all,Tissue enhanced,,bone marrow: 9.0;lung: 14.1,appendix: 3.3,Cell line enhanced,,EFO-21: 13.1;HHSteC: 7.9;U-937: 14.0
88,PCDHA12,PCDH-ALPHA12,ENSG00000251664,Protocadherin alpha 12,5,140875302-141012344,Predicted membrane proteins,Evidence at transcript level,HPA035812,Approved,,Approved,Cytosol,,Not detected,Tissue enhanced,,lung: 2.7,cerebral cortex: 1.8,Cell line enhanced,,A549: 6.8;hTCEpi: 3.3;PC-3: 5.3;RT4: 4.6;SH-SY5Y: 3.3
89,PCSK9,"FH3, HCHOLA3, NARC-1",ENSG00000169174,Proprotein convertase subtilisin/kexin type 9,1,55039548-55064852,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Urothelial cancer:2.40e-4 (unfavourable),Mixed,Tissue enhanced,,liver: 6.1;lung: 11.1,colon: 3.4,Cell line enhanced,,A-431: 72.0;HaCaT: 94.8;HeLa: 62.7;RPTEC TERT1: 39.4
90,PEBP4,"CORK1, hPEBP4, MGC22776",ENSG00000134020,Phosphatidylethanolamine binding protein 4,8,22713251-23000000,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA025064,Uncertain,,,,,Group enriched,Tissue enhanced,,epididymis: 470.5;lung: 173.6;skeletal muscle: 233.0,thyroid gland: 96.3,Cell line enriched,7.0,U-266/70: 3.0
91,PLA2G3,GIII-SPLA2,ENSG00000100078,Phospholipase A2 group III,22,31134809-31140607,"Enzymes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA021016,Uncertain,,,,Head and neck cancer:4.47e-4 (favourable),Mixed,Tissue enhanced,,esophagus: 4.4;lung: 3.6;skin: 10.2,parathyroid gland: 1.5,Group enriched,6.0,AF22: 14.3;AN3-CA: 13.6;NTERA-2: 7.5;SCLC-21H: 13.2
92,PRX,KIAA1620,ENSG00000105227,Periaxin,19,40393768-40413366,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA001868,Enhanced,,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane,,Expressed in all,Tissue enhanced,,lung: 28.8,parathyroid gland: 9.4,Mixed,,
93,PTGIR,IP,ENSG00000160013,Prostaglandin I2 (prostacyclin) receptor (IP),19,46620468-46625118,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable)",Mixed,Tissue enhanced,,lung: 13.9,appendix: 8.2,Cell line enhanced,,BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3
94,RAMP3,,ENSG00000122679,Receptor activity modifying protein 3,7,45157791-45186302,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,"Liver cancer:2.50e-6 (favourable), Cervical cancer:2.89e-4 (favourable)",Expressed in all,Tissue enhanced,,lung: 120.2,thyroid gland: 66.3,Cell line enhanced,,Karpas-707: 1.8
95,RP1,"DCDC4A, ORP1",ENSG00000104237,"RP1, axonemal microtubule associated",8,54554361-54871720,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042257,Supported,,,,,Not detected,Tissue enhanced,,fallopian tube: 16.3;lung: 5.4,testis: 2.4,Cell line enhanced,,HDLM-2: 4.8;RPTEC TERT1: 7.7;U-2197: 2.2
96,RP11-40A7.2,,ENSG00000283526,,9,131545514-131558620,Predicted membrane proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,fallopian tube: 10.2;lung: 6.2,prostate: 4.0,Group enriched,11.0,A549: 13.2;BEWO: 9.2;MCF7: 3.0;T-47d: 6.8
97,RSPO4,"C20orf182, dJ824F16.3",ENSG00000101282,R-spondin 4,20,958452-1002264,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA048887,Uncertain,,,,Endometrial cancer:2.98e-6 (unfavourable),Mixed,Tissue enhanced,,lung: 6.8,testis: 2.4,Cell line enhanced,,BEWO: 3.0;NTERA-2: 6.4;SK-BR-3: 3.3;U-2 OS: 7.7
98,S100A3,S100E,ENSG00000188015,S100 calcium binding protein A3,1,153547329-153549372,Predicted intracellular proteins,Evidence at protein level,"HPA042674, HPA056140",Approved,,Enhanced,Nucleoli<br>Cytosol,Renal cancer:1.61e-6 (unfavourable),Expressed in all,Tissue enhanced,,lung: 19.9;skin: 17.3,esophagus: 7.5,Cell line enhanced,,A549: 71.3;U-2197: 41.8
99,SCTR,,ENSG00000080293,Secretin receptor,2,119439843-119525301,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA007269,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 26.7;lung: 12.7;pancreas: 14.4,stomach: 4.1,Cell line enhanced,,Karpas-707: 2.2
100,SEC14L3,TAP2,ENSG00000100012,SEC14 like lipid binding 3,22,30447959-30472049,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA059450,Uncertain,,,,,Not detected,Tissue enhanced,,bone marrow: 2.3;lung: 1.5;thyroid gland: 2.8,liver: 1.4,Not detected,,
101,SHROOM4,KIAA1202,ENSG00000158352,Shroom family member 4,X,50591647-50814302,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA010565,Uncertain,,,,"Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:8.37e-4 (unfavourable)",Mixed,Tissue enhanced,,lung: 19.2,placenta: 13.1,Cell line enhanced,,EFO-21: 6.5;HUVEC TERT2: 22.2;TIME: 8.3
102,SLC11A1,"LSH, NRAMP, NRAMP1",ENSG00000018280,Solute carrier family 11 member 1,2,218382029-218396894,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA029590,Uncertain,,,,Renal cancer:2.58e-8 (unfavourable),Mixed,Tissue enhanced,,appendix: 9.1;lung: 13.0,spleen: 4.6,Not detected,,
103,SLC39A8,BIGM103,ENSG00000138821,Solute carrier family 39 member 8,4,102251041-102431258,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA038832, HPA038833",Approved,,,,"Renal cancer:6.34e-6 (favourable), Colorectal cancer:1.34e-4 (favourable), Breast cancer:6.69e-4 (favourable)",Expressed in all,Tissue enhanced,,lung: 257.0,"cervix, uterine: 129.4",Cell line enhanced,,BJ hTERT+: 128.9;Karpas-707: 123.0
104,SLC6A14,,ENSG00000268104,Solute carrier family 6 member 14,X,116436622-116461458,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA003193,Uncertain,,Approved,Vesicles,Pancreatic cancer:9.74e-4 (unfavourable),Mixed,Tissue enhanced,,"cervix, uterine: 11.0;lung: 23.9",breast: 9.1,Cell line enhanced,,HeLa: 1.0;Hep G2: 2.3
105,SLC6A5,"GLYT2, NET1",ENSG00000165970,Solute carrier family 6 member 5,11,20599400-20659285,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,lung: 1.4,testis: 0.6,Not detected,,
106,SMAD6,"HsT17432, MADH6, MADH7",ENSG00000137834,SMAD family member 6,15,66702228-66782848,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA061917,,,Supported,Nucleus<br>Nuclear bodies<br>Golgi apparatus,Urothelial cancer:5.45e-5 (favourable),Expressed in all,Tissue enhanced,,lung: 16.8,placenta: 10.7,Cell line enhanced,,EFO-21: 28.0
107,SOSTDC1,"DAND7, DKFZp564D206, USAG1",ENSG00000171243,Sclerostin domain containing 1,7,16461481-16530580,Predicted secreted proteins,Evidence at protein level,,,,,,"Renal cancer:3.22e-5 (favourable), Ovarian cancer:8.69e-4 (favourable), Urothelial cancer:8.72e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,lung: 57.1;stomach: 53.4,kidney: 23.0,Cell line enhanced,,AF22: 8.0;EFO-21: 11.2;NTERA-2: 4.7;RPTEC TERT1: 16.9
108,SPN,"CD43, GPL115, LSN",ENSG00000197471,Sialophorin,16,29662979-29670876,"CD markers, Predicted membrane proteins",Evidence at protein level,"CAB002666, HPA055244",Enhanced,,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cell Junctions,"Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 38.6;lung: 33.3,lymph node: 25.4,Cell line enhanced,,HEL: 209.9;HL-60: 167.0;HMC-1: 98.8;U-937: 115.3
109,SPOCK2,"KIAA0275, testican-2",ENSG00000107742,"SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2",10,72059035-72089032,Predicted secreted proteins,Evidence at protein level,HPA044605,Supported,,Uncertain,Nuclear speckles,"Head and neck cancer:1.95e-5 (favourable), Breast cancer:4.05e-4 (favourable), Melanoma:4.72e-4 (favourable), Ovarian cancer:7.19e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 161.8;lung: 127.8,lymph node: 75.1,Group enriched,8.0,Hep G2: 33.9;SCLC-21H: 79.9
110,ST8SIA6,SIAT8F,ENSG00000148488,"ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6",10,17318383-17454330,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA011635, HPA072708",Uncertain,,Uncertain,Endoplasmic reticulum,,Tissue enhanced,Tissue enhanced,,breast: 13.4;lung: 18.1,epididymis: 9.1,Cell line enriched,8.0,HMC-1: 442.5
111,SUSD2,"BK65A6.2, FLJ22778",ENSG00000099994,Sushi domain containing 2,22,24181259-24189110,Predicted membrane proteins,Evidence at protein level,HPA004117,Enhanced,,Approved,Plasma membrane,Renal cancer:3.29e-5 (unfavourable),Expressed in all,Tissue enhanced,,lung: 139.3,small intestine: 35.2,Cell line enriched,33.0,SK-BR-3: 622.4
112,TBX2,,ENSG00000121068,T-box 2,17,61399896-61409466,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA008586, CAB013636",Approved,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,lung: 50.0,seminal vesicle: 40.0,Cell line enhanced,,AN3-CA: 124.2;MCF7: 62.0;SH-SY5Y: 65.7;WM-115: 44.0
113,TLR8,CD288,ENSG00000101916,Toll like receptor 8,X,12906620-12923169,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA001608,Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 23.2;lung: 15.6;spleen: 18.3,lymph node: 6.6,Not detected,,
114,TMEM100,"FLJ10970, FLJ37856",ENSG00000166292,Transmembrane protein 100,17,55719627-55732121,Predicted membrane proteins,Evidence at protein level,HPA055936,Approved,,Uncertain,Nucleoplasm,"Liver cancer:2.67e-5 (favourable), Renal cancer:1.32e-4 (unfavourable)",Mixed,Tissue enhanced,,lung: 131.2;placenta: 78.3,epididymis: 44.5,Cell line enhanced,,ASC diff: 19.9;ASC TERT1: 13.7;HHSteC: 37.7;HSkMC: 15.0;U-87 MG: 13.6;WM-115: 11.8
115,TMEM125,MGC17299,ENSG00000179178,Transmembrane protein 125,1,43269994-43274002,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA015796,,,Approved,Midbody<br>Cytosol,"Renal cancer:2.91e-9 (favourable), Lung cancer:5.11e-5 (favourable)",Mixed,Tissue enhanced,,lung: 113.7,thyroid gland: 51.5,Cell line enhanced,,A-431: 23.4;BEWO: 21.1;CAPAN-2: 42.6;SK-BR-3: 31.0;T-47d: 31.2
116,TPSD1,,ENSG00000095917,Tryptase delta 1,16,1256059-1258998,"Enzymes, Predicted secreted proteins",Evidence at protein level,"CAB002215, CAB032871, HPA040182, HPA049554",Supported,,Uncertain,Nuclear speckles,,Mixed,Tissue enhanced,,lung: 26.9,gallbladder: 20.3,Group enriched,46.0,HEL: 25.4;HMC-1: 36.4
117,TREM1,"CD354, TREM-1",ENSG00000124731,Triggering receptor expressed on myeloid cells 1,6,41267926-41286719,"CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA005563,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,appendix: 67.7;bone marrow: 63.0;lung: 103.1,adipose tissue: 26.9,Cell line enriched,11.0,U-87 MG: 24.5
118,TREM2,"TREM-2, Trem2a, Trem2b, Trem2c",ENSG00000095970,Triggering receptor expressed on myeloid cells 2,6,41158506-41163186,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA010917, HPA012571",Approved,,,,Liver cancer:4.24e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 37.0;lung: 40.5,adrenal gland: 16.1,Cell line enhanced,,HBEC3-KT: 9.0;hTCEpi: 49.6;THP-1: 26.6
119,VEGFD,"FIGF, VEGF-D",ENSG00000165197,Vascular endothelial growth factor D,X,15345591-15384376,"Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA027342,Uncertain,,,,,Mixed,Tissue enhanced,,breast: 25.0;lung: 59.3,adipose tissue: 13.2,Cell line enhanced,,ASC diff: 2.3;ASC TERT1: 2.0;HSkMC: 2.1
120,VEPH1,"FLJ12604, KIAA1692",ENSG00000197415,Ventricular zone expressed PH domain containing 1,3,157259742-157533619,Predicted intracellular proteins,Evidence at protein level,HPA026645,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Renal cancer:7.75e-9 (favourable),Mixed,Tissue enhanced,,adrenal gland: 26.6;kidney: 28.8;lung: 43.9,epididymis: 21.4,Cell line enhanced,,HUVEC TERT2: 204.2;TIME: 119.8
121,VIPR1,"HVR1, RDC1, VPAC1, VPAC1R",ENSG00000114812,Vasoactive intestinal peptide receptor 1,3,42489299-42537573,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026777,Approved,,,,,Tissue enhanced,Tissue enhanced,,lung: 60.0,duodenum: 34.4,Cell line enhanced,,CAPAN-2: 53.2;RT4: 34.8;WM-115: 77.3
122,XXbac-BPG116M5.17,,ENSG00000244255,,6,31927698-31952048,Predicted secreted proteins,Evidence at protein level,"HPA000951, HPA001817, HPA001832",Approved,,,,,Not detected,Tissue enhanced,,liver: 3.3;lung: 2.9,spleen: 1.2,Not detected,,
123,ZNF385B,"FLJ25270, ZNF533",ENSG00000144331,Zinc finger protein 385B,2,179441982-179861505,Predicted intracellular proteins,Evidence at protein level,HPA046086,,,Supported,Nucleoli fibrillar center,"Renal cancer:1.04e-9 (favourable), Breast cancer:4.86e-8 (favourable)",Group enriched,Tissue enhanced,,lung: 27.5,prostate: 20.0,Cell line enhanced,,Daudi: 12.3;HAP1: 32.8;U-698: 60.0
